The glaucoma therapeutics market was valued at US$ 6.24 billion in 2023 and is expected to reach US$ 8.02 billion by 2031; it is estimated to record a CAGR of 3.2% during 2023-2031.
Key factors driving the market growth are the growing prevalence of glaucoma, rising awareness and early diagnosis of the disease, and increasing product launches are expected to drive the market growth. However, compliance issues with medication regimens and the high cost of treatments hinder the glaucoma therapeutics market growth.
Market Trends of the Glaucoma Therapeutics Market:
The gradual damage of the optic nerve-typically associated with high pressure inside the eye (intraocular pressure)-predominantly due to aging can lead to a group of eye diseases called Glaucoma, which can eventually result in irreversible blindness. One of the most common treatments for glaucoma is to reduce intraocular pressure by using eye drops. However, patient adherence to these eye drops can be challenging, and inadequate patient education can impede treatment success. Additionally, ocular hypotensive drugs can cause local and systemic side effects that may further complicate the treatment. Rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market. Recent advancements in glaucoma therapeutics have revolutionized the available treatments in the market. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the bioavailability and efficacy of the drug. Sustained-release (SR) implants and other innovative drug delivery systems offer improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers in treating POAG. As per the article published in PubMed Central in 2022, the only approved SR therapy for POAG by the Food and Drug Administration (FDA) is Bimatoprost SR (DurystaTM) from Allergan plc. Other SR therapies including bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.
Glaucoma therapeutics Market: Segmental Overview
The glaucoma therapeutics market is segmented on the basis of drug class, indication, and distribution channel.
By drug class, the market is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023. Prostaglandin analogs are the first-line treatment for high intraocular pressure in glaucoma patients. They offer a once-a-day dosing, a significant reduction in intraocular pressure, and low systemic side effects. Thus, the benefits of prostaglandin analogs are responsible for the expansion of the glaucoma therapeutics market size.
The market, by indication, is segmented into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest glaucoma therapeutics market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. Open-angle glaucoma is the most common form of glaucoma, which affects approximately 95% of individuals. Initially, it does not show any symptoms. However, at some point, an individual may start losing their side (peripheral) vision without treatment, resulting in total blindness.
By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023.
Glaucoma therapeutics Market: Geographical Overview
The scope of the glaucoma therapeutics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). Asia Pacific is expected to register the fastest CAGR in the market from 2023 to 2031. Factors such as ongoing clinical studies for developing novel glaucoma therapies, as well as increasing healthcare expenditures in the region, contribute to the glaucoma therapeutics market growth in Asia Pacific. In terms of revenue, North America accounted for the largest glaucoma therapeutics market share in 2023.
TABLE OF CONTENTS
1. Introduction
1.1 Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
 3.2.1 Hypothesis formulation:
 3.2.2 Macro-economic factor analysis:
 3.2.3 Developing base number:
 3.2.4 Data Triangulation:
 3.2.5 Country level data:
4. Glaucoma Therapeutics Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Glaucoma Therapeutics Market - Key Market Dynamics
5.1 Glaucoma Therapeutics Market - Key Market Dynamics
5.2 Market Drivers
 5.2.1 Mounting Incidence of Glaucoma Disease
 5.2.2 Increasing Number of Product Launches, Collaborations, Acquisitions
5.3 Market Restraints
 5.3.1 Medication Regimen Compliance Issues
5.4 Market Opportunities
 5.4.1 Development of Wearable Technologies
5.5 Future Trends
 5.5.1 Development of Novel Drug Delivery Methods
5.6 Impact of Drivers and Restraints:
6. Glaucoma Therapeutics Market - Global Market Analysis
6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
6.2 Glaucoma Therapeutics Market Forecast Analysis
7. Glaucoma Therapeutics Market Analysis - by Drug Class
7.1 Beta Blockers
 7.1.1 Overview
 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Alpha Adrenergic Agonists
 7.2.1 Overview
 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Prostaglandins Analogues
 7.3.1 Overview
 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Carbonic Anhydrase Inhibitors
 7.4.1 Overview
 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Combination Drugs
 7.5.1 Overview
 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
 7.6.1 Overview
 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8. Glaucoma Therapeutics Market Analysis - by Indication
8.1 Open Angle Glaucoma
 8.1.1 Overview
 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Angle Closure Glaucoma
 8.2.1 Overview
 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Others
 8.3.1 Overview
 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9. Glaucoma Therapeutics Market Analysis - by Distribution Channel
9.1 Hospital Pharmacy
 9.1.1 Overview
 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacy
 9.2.1 Overview
 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Online Pharmacy
 9.3.1 Overview
 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
10. Glaucoma Therapeutics Market - Geographical Analysis
10.1 Overview
10.2 North America
 10.2.1 North America Glaucoma Therapeutics Market Overview
 10.2.2 North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.2.3 North America: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.2.3.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 10.2.4 North America: Glaucoma Therapeutics Market Breakdown, by Indication
 10.2.4.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
 10.2.5 North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.2.5.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 10.2.6 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.2.6.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.2.6.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.2.6.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.2.6.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
 10.2.6.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.2.6.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.2.6.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.2.6.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
 10.2.6.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.2.6.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.2.6.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.2.6.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
 10.2.6.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.3 Europe
 10.3.1 Europe Glaucoma Therapeutics Market Overview
 10.3.2 Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.3 Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.3.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 10.3.4 Europe: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.4.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
 10.3.5 Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.5.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 10.3.6 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.3.6.1 Europe: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.3.6.2 Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.2.1 Germany: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.2.2 Germany: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.2.3 Germany: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.6.3 France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.3.1 France: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.3.2 France: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.3.3 France: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.6.4 United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.4.1 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.4.2 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.4.3 United Kingdom: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.6.5 Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.5.1 Italy: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.5.2 Italy: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.5.3 Italy: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.6.6 Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.6.1 Spain: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.6.2 Spain: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.6.3 Spain: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.3.6.7 Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.3.6.7.1 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.3.6.7.2 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Indication
 10.3.6.7.3 Rest of Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.4 Asia Pacific
 10.4.1 Asia Pacific Glaucoma Therapeutics Market Overview
 10.4.2 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.3 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.3.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 10.4.4 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.4.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
 10.4.5 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.5.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 10.4.6 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.4.6.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.4.6.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.6.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.6.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.6.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.6.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.4.6.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.4.6.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.4.6.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
 10.4.6.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.5 Middle East and Africa
 10.5.1 Middle East and Africa Glaucoma Therapeutics Market Overview
 10.5.2 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.5.3 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.5.3.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 10.5.4 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
 10.5.4.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
 10.5.5 Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.5.5.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 10.5.6 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.5.6.1 Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.5.6.2 Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.5.6.2.1 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.5.6.2.2 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Indication
 10.5.6.2.3 Saudi Arabia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.5.6.3 South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.5.6.3.1 South Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.5.6.3.2 South Africa: Glaucoma Therapeutics Market Breakdown, by Indication
 10.5.6.3.3 South Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.5.6.4 United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.5.6.4.1 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.5.6.4.2 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Indication
 10.5.6.4.3 United Arab Emirates: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.5.6.5 Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.5.6.5.1 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.5.6.5.2 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Indication
 10.5.6.5.3 Rest of Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
10.6 South and Central America
 10.6.1 South and Central America Glaucoma Therapeutics Market Overview
 10.6.2 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.6.3 South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.6.3.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Drug Class
 10.6.4 South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
 10.6.4.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Indication
 10.6.5 South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.6.5.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Distribution Channel
 10.6.6 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.6.6.1 South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
 10.6.6.2 Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.6.6.2.1 Brazil: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.6.6.2.2 Brazil: Glaucoma Therapeutics Market Breakdown, by Indication
 10.6.6.2.3 Brazil: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.6.6.3 Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.6.6.3.1 Argentina: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.6.6.3.2 Argentina: Glaucoma Therapeutics Market Breakdown, by Indication
 10.6.6.3.3 Argentina: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
 10.6.6.4 Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
 10.6.6.4.1 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Drug Class
 10.6.6.4.2 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Indication
 10.6.6.4.3 Rest of South and Central America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
11. Glaucoma Therapeutics Market - Industry Landscape
11.1 Growth Strategies in Glaucoma Therapeutics Market
11.2 Organic Growth Strategies
 11.2.1 Overview
11.3 Inorganic Growth Strategies
 11.3.1 Overview
12. Company Profiles
12.1 Alcon AG
 12.1.1 Key Facts
 12.1.2 Business Description
 12.1.3 Products and Services
 12.1.4 Financial Overview
 12.1.5 SWOT Analysis
 12.1.6 Key Developments
12.2 AbbVie Inc
 12.2.1 Key Facts
 12.2.2 Business Description
 12.2.3 Products and Services
 12.2.4 Financial Overview
 12.2.5 SWOT Analysis
 12.2.6 Key Developments
12.3 Bausch & Lomb Inc
 12.3.1 Key Facts
 12.3.2 Business Description
 12.3.3 Products and Services
 12.3.4 Financial Overview
 12.3.5 SWOT Analysis
 12.3.6 Key Developments
12.4 Fera Pharmaceuticals, LLC
 12.4.1 Key Facts
 12.4.2 Business Description
 12.4.3 Products and Services
 12.4.4 Financial Overview
 12.4.5 SWOT Analysis
 12.4.6 Key Developments
12.5 Viatris Inc
 12.5.1 Key Facts
 12.5.2 Business Description
 12.5.3 Products and Services
 12.5.4 Financial Overview
 12.5.5 SWOT Analysis
 12.5.6 Key Developments
12.6 Novartis AG
 12.6.1 Key Facts
 12.6.2 Business Description
 12.6.3 Products and Services
 12.6.4 Financial Overview
 12.6.5 SWOT Analysis
 12.6.6 Key Developments
12.7 Sun Pharmaceutical Industries Ltd
 12.7.1 Key Facts
 12.7.2 Business Description
 12.7.3 Products and Services
 12.7.4 Financial Overview
 12.7.5 SWOT Analysis
 12.7.6 Key Developments
12.8 Teva Pharmaceutical Industries Ltd
 12.8.1 Key Facts
 12.8.2 Business Description
 12.8.3 Products and Services
 12.8.4 Financial Overview
 12.8.5 SWOT Analysis
 12.8.6 Key Developments
12.9 Thea Pharma Inc
 12.9.1 Key Facts
 12.9.2 Business Description
 12.9.3 Products and Services
 12.9.4 Financial Overview
 12.9.5 SWOT Analysis
 12.9.6 Key Developments
12.10 Santen Pharmaceutical Co., Ltd.
 12.10.1 Key Facts
 12.10.2 Business Description
 12.10.3 Products and Services
 12.10.4 Financial Overview
 12.10.5 SWOT Analysis
 12.10.6 Key Developments
13. Appendix
13.1 About
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Glaucoma Therapeutics Market Segmentation
Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 7. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 8. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 9. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 10. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 11. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 12. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 13. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 14. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 15. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 16. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 17. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 18. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 19. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 20. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 21. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 22. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 23. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 24. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 25. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 26. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 27. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 28. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 29. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 30. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 31. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 32. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 33. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 34. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 35. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 36. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 37. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 38. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 40. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 41. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 42. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 43. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 44. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 46. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 47. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 48. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 49. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 50. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 51. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 52. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 53. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 54. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 55. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 56. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 57. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 58. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 59. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 60. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 61. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 62. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 63. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 64. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 65. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 66. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 67. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 68. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 69. Saudi Arabia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 70. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 71. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 72. South Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 73. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 74. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 75. United Arab Emirates: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 76. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 77. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 78. Rest of Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 79. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 80. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 81. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 82. South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 83. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 84. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 85. Brazil: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 86. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 87. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 88. Argentina: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 89. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
Table 90. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
Table 91. Rest of South and Central America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 92. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
Table 93. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
Table 94. Glossary of Terms, Transiaent Protein Expression Market
LIST OF FIGURES
Figure 1. Glaucoma Therapeutics Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
Figure 5. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
Figure 6. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
Figure 13. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
Figure 17. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Glaucoma Therapeutics Market Breakdown by Region, 2023 and 2031 (%)
Figure 21. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
Figure 23. North America: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
Figure 24. North America: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
Figure 25. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 26. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 27. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 28. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 29. Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 30. Europe: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
Figure 31. Europe: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
Figure 32. Europe: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
Figure 33. Europe: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 34. Germany: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 35. France: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 36. United Kingdom: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 37. Italy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 38. Spain: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 39. Rest of Europe: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 40. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 41. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Drug Class (2023 and 2031)
Figure 42. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Indication (2023 and 2031)
Figure 43. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Distribution Channel (2023 and 2031)
Figure 44. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 45. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 46. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 47. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 48. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 49. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 50. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 51. Middle East and Africa: Glaucoma Therapeutics Market - Revenue and Forecast to 2031(US$ Million)
Figure 52. Middle East and Africa: Glaucoma Therapeutics Market Breakdown, by Drug Cla
The List of Companies - Glaucoma Therapeutics Market
Fera Pharmaceuticals
GlaxoSmithKline plc
Bristol Myers Squibb
Eli Lilly and Company
Amgen
MannKind Corporation
Sangamo Therapeutics
SciClone Pharmaceuticals, Inc.
Critical Therapeutics, Inc.
Takeda Pharmaceutical Company